Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Rheumatoid Arthritis

Next Previous
X
Search
Trial Profile

A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Folic acid; Infliximab; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Celltrion

    • Most Recent Events

    • 19 Dec 2022 Results of a post-hoc analysis assessing the efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis, published in the Rheumatology
    • 04 Jun 2022 Results of a post-hoc analysis assessing difference in efficacy outcomes between SC and IV IFX at weeks 30 and 54 presented at the 23rd Annual Congress of the European League Against Rheumatism
    • 31 May 2022 According to a Celltrion Media Release, results of a post-hoc analysis were presented at the Annual European Congress of Rheumatology (EULAR 2022).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top